-
-
-
-
-
-
-
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
-
-
-
-
-
-
-
UCB's fenfluramine meets phase 3 trial goals for rare seizure disorder
-
-
-
-
-
-
-
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
-
-
-
-
-
-
-
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
-
-
-
-
-
-
-
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
-
-
-
-
-
-
-
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
-
-
-
-
-
-
-
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) S
-
1,171,065 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

